Shay Capital LLC and Shay Capital Holdings LLC Schedule 13G Filing for LAVA Therapeutics NV

Shay Capital LLC and Shay Capital Holdings LLC have filed a Schedule 13G with the SEC, disclosing their ownership of common shares in LAVA Therapeutics NV. The filing indicates that each entity beneficially owns 2,596,403 common shares, representing 9.9% of the total shares outstanding. The shares are held with sole voting and dispositive power, and the filing is made pursuant to Rule 13d-1(c). The filing includes a joint filing agreement signed by Elan Foxman, the Chief Financial Officer of both entities, certifying that the shares were not acquired for the purpose of influencing the control of the issuer.